Global Fenofibrate Market Growth 2018-2023

Global Fenofibrate Market Growth 2018-2023

Pharmaceuticals 23/11/2018 167 List Figures TOC

Fenofibrate, marketed as Tricor and under several other brand names, is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in people at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.

According to this study, over the next five years the Fenofibrate market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2023, from US$ xx million in 2017. In particular, this report presents the global market share (sales and revenue) of key companies in Fenofibrate business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Fenofibrate market by product type, application, key manufacturers and key regions and countries.

This study considers the Fenofibrate value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2013 to 2018, in Section 2.3; and forecast to 2023 in section 11.7.
Tablet
Capsule
Segmentation by application: breakdown data from 2013 to 2018, in Section 2.4; and forecast to 2023 in section 11.8.
Hospital
Drug store

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
AbbVie
Lupin
Salix Pharmaceuticals
Vectura
Cipher Pharmaceuticals
Rhodes Pharmaceuticals
Impax Laboratories
Mylan
Teva
Sun Pharmaceutical
Bausch Health
HETERO
Aurobindo Pharma
Cipla
Amneal Pharmaceuticals
Prinston Pharmaceutical
Dr. Reddys Laboratories
APOTEX
Glenmark

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Fenofibrate consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Fenofibrate market by identifying its various subsegments.
Focuses on the key global Fenofibrate manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Fenofibrate with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Fenofibrate submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.